Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

NCCN > CAVT > Flashcards

CAVT Flashcards

1
Q

The NCCN Guidelines Panel for Cancer-Associated Venous Thromboembolic Disease recommends VTE prophylaxis for all patients hospitalized with cancer, excluding
those with _______________.

A

Basal/squamous cell skin cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Has reduced deep vein thrombosis (DVT) and was associated with a lower risk of skin complications compared to graduated compression stockings (GCS)

A

Intermittent pneumatic compression (IPC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

VTE PROPHYLAXIS FOLLOWING DISCHARGE

For Surgical oncology setting, duration of anticoagulation following high-risk abdominal or pelvic cancer surgery:
* Surgery for gastrointestinal (GI) malignancies
* Patients with a previous history of VTE
* Anesthesia time >2 hours
* Bed rest ≥4 days
* Advanced-stage disease
* Patient age >60 years

A

4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

VTE PROPHYLAXIS FOLLOWING DISCHARGE

Medical oncology setting

Patients with cancer (excluding multiple myeloma, acute leukemia, myeloproliferative neoplasms, and patients with primary/metastatic brain tumorsi) receiving/starting systemic therapy for their cancer:

Intermediate or high risk for VTE (Khorana score ≥2):
Low risk for VTE (Khorana score < 2):

A

Intermediate or high risk for VTE (Khorana score ≥2):6 months or longer, if risk persists

Low risk for VTE (Khorana score < 2):No routine VTE prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Contraindications to Prophylactic Anticoagulation

A
  • Active bleeding
  • Thrombocytopenia (platelet count <50,000/μL or clinical judgment)
  • Underlying hemorrhagic coagulopathy (eg, abnormal PT or aPTT excluding a lupus inhibitor/anticoagulant) or known bleeding disorder in the absence of replacement therapy (eg, hemophilia, von Willebrand disease)
  • Indwelling neuraxial catheters (contraindication for apixaban, dabigatran, edoxaban, fondaparinux, rivaroxaban, or enoxaparin dose exceeding 40 mg daily)
  • Neuraxial anesthesia/lumbar puncture
  • Interventional spine and pain procedures
  • Current or previous heparin-induced thrombocytopenia (HIT) (contraindication for LMWH and UFH)

For patients at high risk, prophylactic anticoagulation may be appropriate even if platelet count is as low as 25,000/μL.

Twice-daily prophylactic dose UFH (5000 units every 12 h) and once-daily LMWH (eg, enoxaparin 40 mg once daily) may be used with neuraxial anesthesia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Contraindications to Mechanical Prophylaxis

A

Absolute
* Acute DVT (unless on therapeutic anticoagulation)
* Severe arterial insufficiency (pertains to GCS only)

Relative
* Large hematoma
* Skin ulcerations or woundse
* Mild arterial insufficiency (pertains to GCS only)
* Peripheral neuropathy (pertains to GCS only)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Timing of LMWH: For LMWH, placement or removal of a neuraxial catheter should be delayed for at least _______ hours after administration of prophylactic doses such as those used for prevention of DVT.

Longer delays (24 h) are appropriate to consider for patients receiving therapeutic doses of LMWH.

A

12 hours: prophylactic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Drug that is absorbed in the stomach, proximal small bowel, and colon. Patients who have had significant resections of these portions of the intestinal tract may be at
risk for suboptimal absorption.

A

DOAC

With the exception of apixaban, which is also partially absorbed in the colon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Drug approved for patients with gynecologic cancers.

Was initiated at investigator discretion once epidural anesthesia catheters were removed.
Duration of prophylaxis was 28 days.

A

Apixaban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

DOAC approved for patients after laparoscopic surgery for colorectal cancer

A

Rivaroxaban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

VTE RISK ASSESSMENT IN OUTPATIENTS WITH CANCER

Khorana Predictive Model for Chemotherapy-Associated VTE

A
  • Site of primary cancer
    Very high risk (stomach, pancreas) 2
    High risk (lung, lymphoma, gynecologic, bladder, testicular) 1
  • Prechemotherapy platelet count 350 x 109/L or higher
  • Hemoglobin level less than 10 g/dL or use of red cell growth factors 1
  • Prechemotherapy leukocyte count higher than 11 x 109/L 1
  • BMI 35 kg/m2 or higher

0 Low 0.3–1.5%
1, 2 Intermediate 2.0–4.8%
3 or higher High 6.7–12.9%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Upper extremity SVT

A
  • Median
  • Basilic
  • Cephalic veins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Lower extremity SVT

A
  • Great and small saphenous veins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

When to consider prophylactic dose anticoaguation in Acute Superficial Vein Thrombosis

A
  • Lower extremity SVT >5 cm in length
  • Lower extremity SVT extends above knee

Consider repeat US in 7–10 days if SVT <5 cm in length or below knee. If repeat US shows progression, considernanticoagulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

When to consider therapeutic dose anticoaguation in Acute Superficial Vein Thrombosis

A
  • If the clot is in close proximitye to the deep venous system, 3 cm
  • Lower extremity SVT within 3 cm of the saphenofemoral junction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Symptomatic treatment for SVT includes

A
  • Warm compresses
  • Nonsteroidal anti-inflammatory drugs (NSAIDs), and
  • Elevation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

TRUE OR FALSE

For patients with SVT associated with a peripherally inserted central catheter (PICC) line, catheter removal may not be necessary, especially if the patient is treated with anticoagulation and/or symptoms resolve.

A

TRUE

For patients with SVT associated with a peripherally inserted central catheter (PICC) line, catheter removal may not be necessary, especially if the patient is treated with anticoagulation and/or symptoms resolve.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Clinical signs/symptoms of DVT:

A
  • Swelling of unilateral extremity
  • Heaviness in extremity
  • Pain in extremity
  • Unexplained persistent calf cramping
  • Swelling in face, neck, or supraclavicular space
  • Catheter dysfunction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Types of Venous imaging:

A
  • Venous US
  • CT venogram (CTV) with contrast
  • Magnetic resonance venogram (MRV) with contrast
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

DVT LOCATION

PROXIMAL LOWER EXTREMITY

DISTAL LOWER EXTREMITY

UPPER LIMB/CHEST

A

PROXIMAL LOWER EXTREMITY
* Pelvic/iliac/inferior vena cava (IVC)
* Femoral/popliteal

DISTAL LOWER EXTREMITY
* Peroneal, anterior and posterior tibial, and muscular (soleus and gastrocnemius)

UPPER LIMB/CHEST
* Brachiocephalic, subclavian, axillary, internal jugular,
brachial
* Superior vena cava (SVC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Appropriate candidates for catheter-directed therapy may include:

A
  • Patients at risk of limb loss (eg, phlegmasia cerulea dolens)
  • Patients with central thrombus propagation despite anticoagulation
  • Those with moderate to severely symptomatic proximal
    DVT.

Candidates with high bleeding risk or contraindication to fibrinolytic may be candidates for percutaneous mechanical thrombectomy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Clinical suspicion of catheter-related DVT:

A
  • Unilateral limb swelling
  • Pain in supraclavicular space or neck
  • Dysfunctional catheter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Duration of anticoagulation in CATHETER-RELATED DVT

A

At least 3 months or as long as central venous access device (CVAD) is in placed

Consider catheter removal if symptoms persist or if the catheter is infected or dysfunctional or no longer necessary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

TRUE OR FALSE

Anticoagulation without catheter removal is the preferred option for initial treatment, even for patients with symptomatic DVT, provided that the catheter is necessary, functional, and free of infection.

A

TRUE

Anticoagulation without catheter removal is the preferred option for initial treatment, even for patients with symptomatic DVT, provided that the catheter is necessary, functional, and free of infection.

25
Q

Clinical suspicion of pulmonary embolism (PE):

A
  • Current DVT or recent history of DVT
  • Unexplained shortness of breath, chest pain, tachycardia, apprehension, or tachypnea
  • Syncope
  • Hypoxemia
26
Q

Imaging for PE diagnosis

A
  • CT angiography (CTA) with contrast
  • X-ray pulmonary angiography with contrast (rarely used unless combined with clot extraction or thrombolytic therapy)
  • Magnetic resonance angiography (MRA) with contrast
  • Ventilation/perfusion (VQ) scan (lung scan) if CTA is contraindicated (eg, renal insufficiency, allergy refractory to anaphylaxis prophylaxis)
27
Q

TRUE OR FALSE

D-dimer has limited utility in patients with cancer.

A

TRUE

D-dimer has limited utility in patients with cancer.

28
Q

Hemodynamic instability in PE:

Consider Systemic or catheter-directed thrombolysis or embolectomy

A
  • Acute PE with sustained hypotension (systolic blood pressure <90 mmHg for at least 15 minutes or requiring inotropic support, not due to a cause other than PE, such as
    arrhythmia, hypovolemia, sepsis, or left ventricular [LV] dysfunction), pulselessness, or persistent profound bradycardia (heart rate <40 bpm with signs or symptoms of shock).
29
Q

CLINICAL SUSPICION OF SPVT

A
    • Abdominal or mid-abdominal colicky pain
  • Abdominal distention
  • Rebound tenderness
  • Guarding
  • Fever
  • Anorexia
  • Nausea, vomiting
  • Diarrhea
  • Gastrointestinal (GI) bleeding
  • Hepatomegaly
  • Ascites
30
Q

Risk factors relevant to cancer population for SPVT:

A
  • Recent abdominal surgery (eg, splenectomy)
  • Abdominal mass
  • Pancreatitis
  • Cirrhosis
  • Exogenous estrogens
  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • Myeloproliferative neoplasms associated with the JAK2 V617F mutation (most common) or CALR mutation (rare)
31
Q

Duration of SPVT

Acute
Chronic

A

Duration of SPVT

Acute: ≤8 weeks
Chronic: >8 weeks

32
Q

Considered as one of the management option for patients with SPVT and portal hypertension

A

TIPS

33
Q

Duration of Anticoagulation as Recommended by Guideline:

A
  • Duration should be at least 3 months or as long as active cancer or cancer therapy.
  • For non–catheter-associated DVT or PE recommend indefinite anticoagulation while cancer is active, under treatment, or if risk factors for recurrence persist.
  • For symptomatic catheter-associated DVT, consider anticoagulation treatment for at least 3 months or as long as the catheter is in place.
  • Providers should continue to discuss with patients the risks/benefits of anticoagulation to determine the appropriate duration of therapy.
34
Q

Following initiation of anticoagulant: hemoglobin, hematocrit, and platelet count at least every _______ days for the first ______ days while in the inpatient setting and every 2 weeks thereafter or as clinically indicated.

A

2 to 3 days

First 14 days

35
Q

TRUE OR FALSE

In the absence of contraindications, NCCN suggests that DOACs, LMWH, and warfarin can be considered for reatment of SPVT.

A

TRUE

In the absence of contraindications, NCCN suggests that DOACs, LMWH, and warfarin can be considered for reatment of SPVT.

36
Q

TRUE OR FALSE

In patients with cancer, DOACs and LMWH are preferable to warfarin.

A

In patients with cancer, DOACs and LMWH are preferable to warfarin.

37
Q

If warfarin is selected for chronic anticoagulation, initiate warfarin concurrently with the parenteral agent used for acute therapy and continue both therapies for
at least ____ days and until INR is ____.

A

5 days

INR is ≥2

During the transition to warfarin monotherapy, the INR should be measured at least twice weekly.

Once the patient is on warfarin alone, the INR should be measured initially at least once weekly

Once the patient is on a stable dose of warfarin with an INR of 2–3, INR testing can be gradually decreased to a frequency of no less than once a month.

38
Q

Absolute contraindications to Anticoagulation

A
  • Active bleeding (major)
  • Indwelling neuraxial catheters
  • Neuraxial anesthesia/lumbar puncture
  • Interventional spine and pain procedures1
39
Q

Considered major bleeding:

A
  • Active bleeding with >2 units red blood cells (RBCs) transfused
  • Decrease in hemoglobin by ≥2 g/dL or
  • Intracranial or intraspinal bleeding
40
Q

Relative contraindications to Anticoagulation

A
  • Chronic, clinically significant measurable bleeding >48 hours
  • Thrombocytopenia (platelet count <30,000–50,000/μL or clinical judgment)
  • Underlying hemorrhagic coagulopathy (eg, abnormal PT or aPTT excluding a lupus inhibitor/anticoagulant) or known bleeding disorder in the absence of replacement therapy (eg, hemophilia, von Willebrand disease)
  • Severe platelet dysfunction
  • Recent major operation at high risk for bleeding
  • High risk for falls (head trauma)
  • Primary and metastatic brain tumors
  • Long-term antiplatelet therapy
41
Q

CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA

Generally, anticoagulation is considered safe with platelet counts ____________.

A

≥50,000/μL

42
Q

Enoxaparin Dose Modification in the Setting of Thrombocytopenia

> 50,000/μL:
25,000–50,000/μL:
<25,000/μL:

A

> 50,000/μL: 1 mg/kg twice daily or 1.5 mg/kg daily
25,000–50,000/μL: 0.5 mg/kg twice daily
<25,000/μL Temporarily hold enoxaparin:

43
Q

Testing done for patients with progression or new
thrombosis on therapeutic anticoagulation with drug on Therapeutic level:

A

Consider HIT and antiphospholipid
syndrome (APS) testing

Also consider conditions associated with venous stasis such as vascular compression by tumors or lymphatic masses or stasis associated with IVC filters.

44
Q

Tests to measure drug level:

UFH:
LMWH:
Fondaparinux:
Warfarin:
Apixaban:
Dabigatran:
Edoxaban:
Rivaroxaban:

A

UFH: UFH anti-Xa or aPTT
LMWH: LMWH anti-Xa
Fondaparinux: Fondaparinux anti-Xa
Warfarin: INR
Apixaban: Apixaban anti-Xa
Dabigatran: Ecarin clotting time or diluted thrombin time (dTT)
Edoxaban: Edoxaban anti-Xa
Rivaroxaban Rivaroxaban anti-Xa

45
Q

Thrombolytic agents used in DVT and PE

A
  • Alteplase
  • Reteplase
  • Tenecteplase (only on PE)
46
Q

Indications for Thrombolysis:

A
    • Limb-threatening/life-threatening acute proximal DVT
    • Symptomatic iliofemoral thrombosis
    • Massive/life-threatening PE
    • Intestinal SPVT with high risk of ischemia
47
Q

Absolute Contraindications to Thrombolysis

A
  • History of hemorrhagic stroke or stroke of unknown origin
  • Intracranial tumor
  • Ischemic stroke in previous 3 months
  • History of major trauma, surgery, or head injury in previous 3 weeks
  • Active bleeding
  • Bleeding diathesis
48
Q

Relative Contraindications to Thrombolysis

A
  • Age >75 years
  • Pregnancy or first postpartum week
  • Non-compressible puncture sites
  • Traumatic resuscitation
  • Platelet count <100,000/μL
  • Refractory hypertension (systolic pressure >180 mmHg; diastolic blood pressure >100 mmHg)
  • Advanced liver disease
  • Infective endocarditis
  • Recent GI bleed (last 3 months)
  • Life expectancy ≤1 year
49
Q

Reversal for UFH, LMWH

A

Protamine

Dose
UHF and Dalteparin: 1 mg/100 units
Enoxaparin: 1 mg/mg of enoxaparin

Maximum dose: 50 mg

  • Protamine 1 mg/mg of enoxaparin or 1 mg/100 units of dalteparin within 8 hours of dose
  • Protamine 0.5 mg/mg of enoxaparin or 0.5 mg/100 units of dalteparin if dose administered >8 hours prior
50
Q

No specific antidote exists for:

A

Bivalirudin
Argatroban
Fondaparinux

51
Q

Reversal for Dabigatran

A

Idarucizumab

Dose: 2.5 g in 2 consecutive boluses

Oral charcoal if dose within 2 hours of ingestion
Hemodialysis
Hemodialysis with a charcoal filter

52
Q

Reversal for Rivaroxaban, Apixaban, Edoxaban

A

Andexanet alfa

Alternative options may include:
◊ aPCC 25–50 units/kg IV
◊ 4-factor PCC 25–50 units per kg (based on units of Factor IX per kg of actual body weight) or fixed dose of 2000 units
◊ If 4-factor PCC is unavailable or patient is allergic to heparin and/or has a history of HIT in the last 12 months, then administer 3-factor PCC 50 units/kg (based on units of Factor IX per kg of actual body weight)

53
Q

The impact of warfarin dose changes can take at least ______ days to be fully manifested in the INR.

A

5 to 7 days

54
Q

Reversal for Warfarin

INR 4.5–10, no bleeding:
INR >10, no bleeding:

A

INR 4.5–10, no bleeding: Follow INR closelyc (at least daily as an inpatient, every 1–2 days as outpatient).

INR >10, no bleeding: Small dose of oral vitamin K1 1–2.5 mg in patients at high risk of bleeding

INR 4.5–10, no bleeding: restart warfarin at reduced dose (10%–20% dose reduction)
INR >10, no bleeding: restart warfarin at reduced dose (at least 20% dose reduction)

55
Q

Reversal for Warfarin

Management of urgent surgery

Within 24 hours:
Within 48 hours:

A

Within 24 hours: vitamin K 1–2.5 mg IV slowly
Repeat INR preoperative to determine need for supplemental FFP

Within 48 hours: vitamin K 2.5 mg orally
Repeat INR at 24 and 48 hours to assess need for supplemental vitamin K or FFP

56
Q

Reversal for Warfarin

Life-threatening bleeding

A
  • Vitamin K 10 mg
  • 4-factor PCC
  • FFP 15 mL/kg: 4-factor PCC unavailable or patient is allergic to heparin and/or a history of HIT in the last 12 months
  • rhFVIIa 25 mcg/kg
57
Q

HighBleeding Risk Procedures

A
  • Neurosurgical procedure (intracranial or spinal)
  • Cardiac surgery
  • Urologic surgery
58
Q

High Thromboembolic Risk Procedures

A
  • Mitral mechanical valve (bileaflet)
  • Single-leaflet or caged-ball mechanical valve
  • Mechanical valve with recent stroke (<3 months)
  • Atrial fibrillation (CHADSVasc ≥7)
  • Atrial fibrillation with recent stroke (<3 months)
  • Recent embolic stroke (<3 months)
  • VTE within 3 months
  • High-risk inherited thrombophilia (antithrombin deficiency, protein C deficiency, protein S deficiency, homozygous
    Factor V Leiden or prothrombin gene mutation, compound heterozygous Factor V Leiden/prothrombin gene mutation
    or other combined thrombophilic defects [eg, Factor V Leiden + protein C deficiency])
  • APS
  • Active high thrombotic risk cancera with previous thromboembolism
59
Q

High thrombotic risk cancers include

A
  • Pancreatic
  • Liver
  • Biliary
  • Lung
  • Stomach
  • Brain
  • Esophageal

Non-high thrombotic risk cancers include all other cancers, excluding non-melanoma skin cancer.

NCCN (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions